AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Atrium Therapeutics, Inc. Common Stock (NASDAQ:RNA)
12.76 USD
+0.390 3.153%Sponsored Reports
Loading...
| Previous Close (in USD) | 12.37 |
|---|---|
| Change | +0.390 3.153% |
| 52 W H/L (in USD) | 30.840/4.825 |
| EBITDA (in USD) | -252.838M |
| PE Ratio | -- |
| Volume | 247277 |
| Diluted Eps TTM | -2.96 |
| Total Assets (in USD) | 628.555M |
|---|---|
| Total Liabilities (in USD) | 127.791M |
| Revenue TTM (in USD) | 10.87M |
| Cash (in USD) | 185.082M |
| Market Cap (in USD) | 2,551.590 M |
| Revenue Per Share TTM | 0.141 |
| Gross Profit TTM (in USD) | -141.18M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
10578 Science Center Drive, San Diego, CA, United States, 92121
858 401 7900
Employees: 253
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder & Chairman | 1969 |
| 2. | Ms. Sarah Boyce | Pres, CEO & Director | 1972 |
| 3. | Mr. Michael F. MacLean | Chief Financial & Bus. Officer | 1966 |
| 4. | Dr. W. Michael Flanagan Ph.D. | Chief Technical Officer | 1962 |
| 5. | Dr. Arthur A. Levin Ph.D. | Chief Scientific Officer | 1954 |
| 6. | Prof. Mark E. Davis | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s | NA |
| 7. | Dr. Frank McCormick Ph.D. | Scientific Founder & Member of Scientific Advisory Board | 1950 |
| 8. | Ms. Kathleen Gallagher | Sr. VP of Corp. Communications & Investor Relations | NA |
| 9. | Dr. John W. Wallen III | VP of Intellectual Property, Gen. Counsel & Sec. | 1958 |
| 10. | Ms. Teresa McCarthy | Chief HR Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.040 0.091% | 44.69 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.400 0.909% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.535 1.244% | 446.685 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.840 0.464% | 613.35 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -173.995M | -118.009M | -44.355M | -24.734M | -11.216M |
| Minority Interest | - | - | - | - | - |
| Net Income | -169.077M | -117.37M | -43.982M | -32.121M | -11.934M |
| Selling General Administrative | 37.733M | 26.195M | 13.462M | 5.112M | 2.441M |
| Gross Profit | 9.224M | 9.326M | 6.787M | 2.319M | 0.379M |
| Reconciled Depreciation | 1.387M | 0.639M | 0.373M | 0.348M | 0.383M |
| Ebit | -180.3M | -118.69M | -44.65M | -17.332M | -10.498M |
| Ebitda | -178.913M | -118.051M | -44.277M | -16.984M | -10.115M |
| Depreciation And Amortization | 1.387M | 0.639M | 0.373M | 0.348M | 0.383M |
| Operating Income | -178.913M | -118.051M | -44.277M | -17.332M | -10.498M |
| Other Operating Expenses | 188.137M | 127.377M | 51.064M | 19.651M | 10.877M |
| Interest Expense | 5.69M | 0.639M | 0.209M | 7.387M | 0.718M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 4.975M | 0.104M | 0.206M | 0M | 0M |
| Net Interest Income | 4.975M | 0.104M | -0.003M | -7.387M | -0.718M |
| Income Tax Expense | -4.918M | -0.639M | -0.373M | 7.387M | 0.718M |
| Total Revenue | 9.224M | 9.326M | 6.787M | 2.319M | 0.379M |
| Total Operating Expenses | 188.137M | 127.377M | 51.064M | 19.651M | 10.877M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 4.918M | 0.042M | -0.078M | -7.402M | -0.718M |
| Net Income From Continuing Ops | -173.995M | -118.009M | -44.355M | -24.734M | -11.216M |
| Net Income Applicable To Common Shares | -173.995M | -118.009M | -44.355M | -24.734M | -11.216M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 628.555M | 638.8M | 427.58M | 333.898M | 96.907M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 14.051M | 12.215M | 5.598M | 3.537M | 1.098M |
| Total Liab | 127.791M | 60.725M | 46.15M | 27.675M | 162.264M |
| Total Stockholder Equity | 500.764M | 578.075M | 381.43M | 306.223M | -65.357M |
| Other Current Liab | 39.867M | 39.125M | 23.025M | 10.897M | 1.314M |
| Common Stock | 0.008M | 0.007M | 0.005M | 0.004M | 0.001M |
| Capital Stock | 0.008M | 0.007M | 0.005M | 0.004M | 0M |
| Retained Earnings | -570.764M | -358.544M | -184.549M | -66.54M | -22.185M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 0.849M | 0.85M | 0.298M | 0.6M |
| Cash | 185.082M | 340.396M | 405.543M | 328.141M | 94.578M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 80.68M | 51.908M | 29.658M | 14.587M | 10.236M |
| Current Deferred Revenue | 28.365M | 5.041M | 4.864M | 3.69M | 3.84M |
| Net Debt | -175.23M | -329.709M | -395.583M | -327.203M | -89.641M |
| Short Term Debt | 3.639M | 3.105M | 1.769M | 2.774M | 2.774M |
| Short Long Term Debt | - | - | - | - | 2.774M |
| Short Long Term Debt Total | 9.852M | 10.687M | 9.96M | 0.938M | 4.937M |
| Other Stockholder Equity | 1071.395M | 939.31M | 566.161M | 38.866M | -43.172M |
| Property Plant Equipment | - | 15.009M | 15.589M | 1.922M | 0.631M |
| Total Current Assets | 611.307M | 622.942M | 411.141M | 331.678M | 95.676M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 410.269M | 270.331M | 85.095M | 6.679M | - |
| Net Receivables | 1.905M | 2.1M | 0.9M | 1.2M | 0.8M |
| Long Term Debt | - | - | - | - | 1.77M |
| Inventory | - | - | - | - | - |
| Accounts Payable | 8.809M | 4.637M | 14.085M | 7.745M | 2.308M |
| Accumulated Other Comprehensive Income | 0.125M | -2.698M | -0.187M | -0.005M | -1.643M |
| Non Currrent Assets Other | 0.301M | 0.849M | 0.85M | 0.752M | 0.6M |
| Non Current Assets Total | 17.248M | 15.858M | 16.439M | 2.22M | 1.231M |
| Capital Lease Obligations | 9.852M | 7.582M | 11.729M | 0.938M | 0.393M |
| Long Term Debt Total | - | - | - | - | 1.77M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -189.955M | -78.777M | -6.693M | -0.235M | -0.049M |
| Total Cashflows From Investing Activities | -189.955M | -82.517M | -7.785M | -0.235M | -0.049M |
| Total Cash From Financing Activities | 346.171M | 176.316M | 272.037M | 89.233M | 5.144M |
| Net Income | -173.995M | -118.009M | -44.355M | -24.734M | -11.216M |
| Change In Cash | 19.948M | -1.014M | 227.135M | 91.488M | -4.56M |
| Begin Period Cash Flow | 320.699M | 321.713M | 94.578M | 3.09M | 7.65M |
| End Period Cash Flow | 340.647M | 320.699M | 321.713M | 94.578M | 3.09M |
| Total Cash From Operating Activities | -136.268M | -94.813M | -37.117M | 2.49M | -9.655M |
| Depreciation | 1.387M | 0.639M | 0.373M | 0.348M | 0.383M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | 0M | 0.444M | 0.106M | 0.106M |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 0.444M | 72.688M | 0.162M |
| Other Cashflows From Financing Activities | 1.392M | -9.623M | -21.36M | 92.074M | -0.049M |
| Capital Expenditures | 2.823M | 3.74M | 1.092M | 0.235M | 0.049M |
| Change In Working Capital | 9.816M | 5.338M | 2.332M | 19.123M | 0.671M |
| Other Non Cash Items | -0.615M | 0.163M | 0.139M | 7.347M | 0.447M |
| Free Cash Flow | -139.091M | -98.553M | -38.209M | 2.255M | -9.704M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price New Horizons | 2 years ago | 3911225 |
| 2. | US Small-Cap Growth II Equity Comp | 2 years ago | 3911225 |
| 3. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 3439671 |
| 4. | T. Rowe Price Health Sciences | 2 years ago | 3080014 |
| 5. | Fidelity Growth Company Fund | 2 years ago | 2439944 |
| 6. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 2111188 |
| 7. | iShares Russell 2000 ETF | 2 years ago | 1721777 |
| 8. | SPDR® S&P Biotech ETF | 2 years ago | 1560320 |
| 9. | Artisan International Small-Mid Investor | 2 years ago | 1457894 |
| 10. | Artisan Non-U.S. Small-Mid Growth Comp | 2 years ago | 1457894 |
| 11. | Fidelity Select Health Care | 2 years ago | 1200000 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 993671 |
| 13. | Fidelity Growth Company K6 | 2 years ago | 899633 |
| 14. | T. Rowe Price Integrated US Sm Gr Eq | 2 years ago | 805367 |
| 15. | Fidelity Advisor Health Care I | 2 years ago | 800000 |
| 16. | Fidelity Select Biotechnology | 2 years ago | 755811 |
| 17. | Fidelity Small Cap Index | 2 years ago | 755701 |
| 18. | T. Rowe Price New Horizons Tr-Z | 2 years ago | 702159 |
| 19. | iShares Russell 2000 Value ETF | 2 years ago | 688482 |
| 20. | Fidelity Select Pharmaceuticals Port | 2 years ago | 630200 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 2 years ago | 10404096 |
| 2. | T. Rowe Price Associates, Inc. | 2 years ago | 6912661 |
| 3. | RTW INVESTMENTS, LLC | 2 years ago | 6689789 |
| 4. | BlackRock Inc | 2 years ago | 6496593 |
| 5. | COWEN AND COMPANY, LLC | 2 years ago | 5629103 |
| 6. | Vanguard Group Inc | 2 years ago | 4043179 |
| 7. | State Street Corporation | 2 years ago | 3438328 |
| 8. | venBio Select Advisor LLC | 2 years ago | 2510000 |
| 9. | RA Capital Management, LLC | 2 years ago | 2454533 |
| 10. | Artisan Partners Limited Partnership | 2 years ago | 2103022 |
| 11. | Adage Capital Partners Gp LLC | 2 years ago | 1600000 |
| 12. | Geode Capital Management, LLC | 2 years ago | 1547214 |
| 13. | Dimensional Fund Advisors, Inc. | 2 years ago | 1499773 |
| 14. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1490743 |
| 15. | Balyasny Asset Management LLC | 2 years ago | 1215837 |
| 16. | Casdin Capital, LLC | 2 years ago | 1175750 |
| 17. | Boxer Capital LLC | 2 years ago | 1121327 |
| 18. | JPMorgan Chase & Co | 2 years ago | 967903 |
| 19. | Alethea Capital Management, LLC | 2 years ago | 854651 |
| 20. | Logos Global Management LP | 2 years ago | 775000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...